The primary aims of this proposal are 1) that the UCSF ACTU will continue to provide a major scientific leadership role in the ACTG system with the goal of effectively and efficiently identifying and addressing clinical research questions relevant to improving therapeutic interventions for HIV infection and its associated conditions and 2) that the UCSF ACTU will continue to contribute significantly to the multicenter ACTG effort by the timely and appropriate accrual of patients into trials, collection of high quality data, analysis and publication of this data. The methods for achieving these aims involve the design and implementation of prospective clinical trials with particular emphases on 1) developing new therapeutic agents from initial trials in human subjects to final approval by the FDA and 2) transferring effective therapies from the research setting to routine patient care. The UCSF ACTU contribution to this cooperative effort requires continued support for 1) the cadre of experienced clinical investigators who have developed expertise in trial design, implementation and analysis (evidenced by their scientific and leadership contributions to the ACTG over the past five years) and 2) the highly competent and dedicated, experienced clinical research staff, including research nursing, pharmacy and data management personnel that has demonstrated its capability to efficiently collect data that meets rigorous QA/QC standards. In order to improve generalizability of ACTG trial results to minority and women patient subpopulations, a targeted effort is planned that will improve accrual and retention of these patients in ACTG trials. This effort will include development of an outreach program from the SFGH primary site involving linkages with local CPCRA and NIDA units and community clinics, involvement of a proactive local CAB, addition of investigators with expertise on women's and minority HIV issues, and the addition of a subunit in East Oakland (a primarily African-American community). In order to increase participation in the high priority areas if OI's and neurologic complications, existing subunits with a priority focus in each of these two areas will continue to be employed.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (56))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Kempen, John H; Sugar, Elizabeth A; Varma, Rohit et al. (2014) Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections. Ophthalmology 121:2317-24
Kozak, Igor; Vaidya, Vijay; Van Natta, Mark L et al. (2014) The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Invest Ophthalmol Vis Sci 55:4304-12
Amorosa, Valerianna K; Luetkemeyer, Anne; Kang, Minhee et al. (2013) Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. HIV Clin Trials 14:274-83
Jabs, Douglas A; Ahuja, Alka; Van Natta, Mark et al. (2013) Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 120:1262-70
Gangaputra, Sapna; Drye, Lea; Vaidya, Vijay et al. (2013) Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 155:206-212.e5
Kempen, John H; Sugar, Elizabeth A; Lyon, Alice T et al. (2012) Risk of cataract in persons with cytomegalovirus retinitis and the acquired immune deficiency syndrome. Ophthalmology 119:2343-50
Gangaputra, Sapna; Kalyani, Partho S; Fawzi, Amani A et al. (2012) Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with disease-associated factors and mortality. Am J Ophthalmol 153:434-444.e1
Kalyani, Partho S; Fawzi, Amani A; Gangaputra, Sapna et al. (2012) Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with visual function. Am J Ophthalmol 153:428-433.e1
Sezgin, Efe; van Natta, Mark L; Ahuja, Alka et al. (2011) Association of host genetic risk factors with the course of cytomegalovirus retinitis in patients infected with human immunodeficiency virus. Am J Ophthalmol 151:999-1006.e4
Puhan, Milo A; Ahuja, Alka; Van Natta, Mark L et al. (2011) Interviewer versus self-administered health-related quality of life questionnaires - does it matter? Health Qual Life Outcomes 9:30

Showing the most recent 10 out of 82 publications